A REVIEW OF THEOPHYLLINE’S PHARMACOLOGICAL INTERACTIONS WITH MEDICINAL HERBS

Issam Mohammed Abushammala* and Abdallah Mohammed Hamdan

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University- Gaza, P.O Box: 1277, Gaza, Palestine.

Theophylline (TPH) is a bronchodilator with a limited therapeutic index and high inter-individual pharmacokinetic (PK) variability. In this paper, the interactions between TPH and medicinal herbs recorded in the literature were summarized. The collected references in the analyzed literature were investigated. A decrease in TPH bioavailability by induction mechanism on CYP1A2 was reported during co-administration of herbs or herbal extracts as (Andrographis paniculata, Commiphora myrrha, Ephedra species, Evodia rutacearpa, Lepidium sativum, Sophora flavescens, Salvia miltiorrhiza, and Trigonella foenum-graecum). TPH bioavailability was increased by inhibition mechanism on CYP1A2 when co-administered with herbs (Acacia catechu, Angelica species, Astragalus species, Cassia auriculata, Cardiospermum halicacabum and Scutellariae baicalensis. Meanwhile, concomitant use of TPH with (Cassia occidentalis, Glycyrrhiza glabra, Ginkgo biloba, Hypericum perforatum, Nigella sativa, Punica granatum and Rhodiola rosea) was reported to be insignificant. In this review, we focus on the interactions between TPH and medicinal herbs that haven't been covered in prior studies. To reduce the patients' health risks, health professionals involved in their treatment are expected to be thoroughly educated about the interactions between TPH and medicinal plants.

Keywords: Theophylline, Herb-Drug Interaction, CYP1A2, Pharmacology, Bioavailability.

INTRODUCTION

TPH has been one of the most prescribed drugs for the treatment of asthma and chronic obstructive pulmonary disease for more than 70 years. TPH is a bronchodilator with a limited therapeutic index, ranging from 5 to 20 µg/mL. Because of its restricted therapeutic range and high inter-individual PK variability, therapeutic monitoring of TPH serum levels is essential. The hepatic microsomal mono-oxygenase system's cytochrome P450 (CYP) 1A and, to a lesser extent, CYP2E oxidize TPH via N-demethylation and 8-hydroxylation pathways, respectively. The enzymes CYPs play a crucial role in drug metabolism. Approximately 90% of all marketed drugs are metabolized by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Medicine interactions and safety issues can be caused by substantial inhibition or induction of CYP isoenzymes.

Concerns about herb–drug interactions have risen as natural treatments, also known as phytotherapy or phytomedicine, have grown globally for therapeutic purposes. These interactions, which might be pharmacodynamic or PK, are especially significant for treatments with limited therapeutic thresholds. As a result, it is probable that pretreatment with prescriptions or herbal remedies that modify CYP1A activities will affect the PK parameters of TPH. As a result, drug-drug or herb-drug interactions could influence TPH's treatment. Therefore, these interactions may affect therapeutic dose, effectiveness, and toxicity of TPH. In a several of laboratories, animal, and human research, potential herbal medicine-drug interactions have been reported. Herbal medicines have also been demonstrated to
interact clinically with a variety of conventional medications. Inhibition of CYP1A2 activity may increase plasma TPH concentration by inhibiting hepatic clearance and may contribute to the emergence of adverse effects. In contrast, induction of CYP1A2 may reduce plasma TPH to subtherapeutic concentrations. The most hazardous drug interactions are caused by another co-administered drug, food, or natural substance that interferes with the metabolic clearance of one drug. An extensive review of published studies in the PubMed database, Research gate, Google Scholar, Science Direct, and recent conference papers was performed to attain comprehensive publications. “Tables (1-3) show an overview of commonly used herbs”, the results of herb-TPH interactions, and the associated mechanisms.

**Herbs with inductive effect on tph metabolism**

**Andrographis paniculata**

Andrographis paniculata, also known as kalmegh or chuanxinlian, is a herb used to cure common colds, diarrhea, and fever caused by infectious diseases in Asia. The major bioactive components of *A. paniculata* are andrographolide (ANGD) and neoandrographolide. These compounds exhibit anti-inflammatory, anticancer, anti-platelet aggregation, antiviral, and hepatoprotective activities. The CYP450 family, CYP1A1 and CYP1A2 mRNAs were significantly induced by ANGD but, the entire extract of the herb suppressed the activities of CYP1A2, CYP2C in rat and human liver microsomes. In a recent in vitro investigation, it was discovered that ANGD inhibited the NF kappa B pathway, which could have a therapeutic effect in the treatment of asthma. According to the results from an animal study, the clearance (CL) of TPH was dramatically raised and the area under the curve (AUC) was reduced in both pretreatment groups with ANGD and *A. paniculata* extract at low-dose administered TPH (1 mg/kg). When high-dose TPH (5 mg/kg) was given to the ANGD pretreatment group, the elimination half-life ($t_{1/2}$) and mean residence time (MRT) of TPH were decreased by 14% and 17%, respectively. This phenomenon found that other additional herbal components present in *A. paniculata* may interact with CYP1A2 substrate drugs like TPH, slowing its clearance mainly when TPH is given at large doses.

**Commiphora myrrha**

Briefly, myrrh is a dried oleo-gum resin of *Commiphora myrrha* (Burseraceae). Myrrh contains volatile oil (1.5–17%) composed of limonene, dipentene, pinene, eugenol, cinnamaldehyde and others, as well as up to 40% resins consisting of α-, β-, and γ-commiphoric acids. Myrrh oil is used as a flavor ingredient or fixative in soaps, detergents, creams, lotions, and scents. It can be used as a flavoring agent in food. In Ayurveda medicine, it has rejuvenating properties. It also has a historic place in traditional Chinese medicine (TCM). It is used to treat sinusitis, pharyngitis and bronchial complaints such as asthma. It was observed in an animal study that significant differences were present in maximum blood concentration ($C_{max}$), area under moment curve (AUMC), AUC, $t_{1/2}$ and MRT of TPH when co-administered with *C. myrrha*, which affected metabolism and elimination of TPH. The markedly decreased $C_{max}$ and AUC$_{0-t}$ of TPH caused by co-administration with *C. myrrha* indicated that oral bioavailability of TPH was significantly reduced. This study has demonstrated that *C. myrrha* interferes with the PK of TPH at varying degrees in rabbits. Clinical investigations are advised for the safe use of *C. myrrha* with CYP1A substrates.

**Ephedra species**

In asthma therapy, health professionals commonly prescribed herbal drugs containing *Ephedra*, alone or in a combination with Liquorice which may be prescribed by physicians with TPH, a commonly antiasthmatic drug and a typical CYP1A2 substrate. In a PK experiment, the rats were given oral TPH (10 mg/kg/day) pretreated with EWD (18 g/kg) and MXCT (0.2 g/kg) for 14 days. When compared to the control groups, the AUC$_{0-24}$ hr and $C_{max}$ of TPH were markedly lowered. The authors demonstrated that pretreatment with EWD or MXCT increased CYP1A2 activity, which sped up the metabolism of TPH. The administration of
EWD or MXCT with TPH at the same time may decrease the effect of TPH in rats.

**Evodia rutaecarpa**

Many studies have indicated that traditional Chinese herbs are beneficial in the prevention and treatment of a variety of diseases. *Evodia rutaecarpa* (Wu-Chu-Yu) is still China's most popular and multi-purpose herb for treating headaches, abdominal pains, postpartum bleeding, diarrhea, and amenorrhea. One of the interesting alkaloids isolated from *E. rutaecarpa* is rutaecarpine. It has a broad range of biological actions, including vasodilator, inotropic, platelet aggregation inhibitor, and anti-inflammatory properties.

In the rat model, the ethanolic extract of *E. rutaecarpa* fruit (1 and 2 g/kg/day) was given orally to rats for three consecutive days and on the fourth day TPH was administered (2 mg/kg, IV). PK data were calculated by a non-compartmental model. The results elucidated that the TPH level was significantly decreased by concomitant administration with the extract in a dose-related manner. *E. rutaecarpa* may be a selective and potent inducer of the CYP1A enzymes which are responsible for oxidative biotransformation of drugs such as TPH.

**Fenugreek and garden cress**

Fenugreek is the dried ripe seeds of *Trigonella foenum-graecum* (Fabaceae). Simple alkaloids such as trigonelline, gentianine, and saponin account for the majority of fenugreek's components. It has long been utilized in nutrition and in the treatment of kidney problems, diabetes mellitus, cellulitis, and tuberculosis. Fenugreek has also been used in hypercholesterolemia, coagulation diseases, enhancement of breast milk production, and increasing male sexual desire.

Garden cress is the dried ripe seeds of *Lepidium sativum* (Cruciferae). Glucosinolates are the primary constituents of *Lepidium sativum*. Ascorbic acid, cucurbitacins, and cardenolides are some of the other compounds. It can be beneficial for respiratory disorders, vitamin C deficiency, constipation, poor immunity, and as a diuretic. Its seeds are used by Indian medicine practitioners to treat dysentery, as well as fever and catarrhal infections.

A study investigated the influence of fenugreek and garden cress on the PK of TPH in beagle dogs. Results showed that treatment with fenugreek led to a decrease in $C_{\text{max}}$ and $AUC_{0-4}$ of TPH of about 28% and 22%, respectively. Garden cress produced a smaller decrease in $C_{\text{max}}$ and delayed time of peak concentration ($t_{\text{max}}$) of TPH, while $AUC_{0-4}$ increased by about 37.44%.

The concurrent use of TPH with fenugreek or garden cress can make changes in the PKs of TPH in an animal model.

**Sophora flavescens**

*Sophora flavescens*, (Fabaceae), also known as Kushen, is still an important herb in TCM. *S. flavescens* has been extensively used, mainly as an adjuvant with other medicinal herbs to treat fever, dysentery, jaundice, oliguria, asthma, and inflammatory disorders. A large number of compounds have been isolated from *S. flavescens*. The major components that have been identified are flavonoids and alkaloids. At least 50 pure chemicals from *S. flavescens* have been found to have anticancer, antibacterial, antipyretic, anti-nociceptive, and anti-inflammatory properties in many in vitro and in vivo studies.

Effects of *S. flavescens* extract on TPH-metabolizing CYPs and the PK profile of TPH were tested in rats to evaluate this suggested interaction.

TPH-8-oxidation and N-demethylation activities were stimulated after *S. flavescens* extract was administered. The rise in oxidative activities corresponded to an increase in the protein levels of CYP1A2, CYP2B1/2, CYP2C11, and CYP3A. Both AUC and AUMC were reduced after the extract administration. These results demonstrated that *S. flavescens* decreased TPH blood concentration by accelerating the elimination process.

**Salvia miltiorrhiza**

Danshen, the common name of the dried root of *Salvia miltiorrhiza*, is used in TCM to promote circulation and blood stasis. It also treats and prevents coronary artery diseases, hyperlipidemia, and cerebrovascular illnesses. The amount of tanshinones (diterpene quinones), salvianolic acid and polyphenolic acids in the extract can be identified to standardize the danshen products.
According to limited in vitro and animal research, danshen extracts tend to modulate the activities of several CYP450 isoenzymes. However, these effects did not appear to be clinically relevant except a study published by Kuo and collaborators in 2006 in mice demonstrated that extract of danshen in ethyl acetate, which is not used in pharmaceutical preparations, induced the activity of the CYP1A2 isoenzyme by about 60%.\textsuperscript{38} In a separate crossover designed study, 12 healthy volunteers were given a single 100 mg dose of TPH alone, followed by 14 days of taking 4 tablets, each containing 1 g of danshen extract, thrice a day. Danshen slightly reduced the duration to maximal TPH levels, but this was not expected to have any clinical implications, and no other PK parameters were changed.\textsuperscript{39} The inductive effect of Danshan on isoenzyme CYP1A2 is likely due to Danshan's alcoholic extracts rather than aqueous extracts.

**Herbs with inhibitory effect on tph metabolism**

**Acacia catechu**

The heartwood extract of *Acacia catechu*, has pharmacological actions such as immune-modulatory, antipyretic, hepatoprotective, and antioxidant activities. *Acacia catechu* is mostly used in traditional or folk medicine, mainly in Asia.\textsuperscript{40-43} An animal study of pretreated rabbits with extract of heartwood resulted in highly elevation of TPH $C_{max}$, $t_{max}$, and AUC which was about 41.32%, 35.71% and 15.03%, respectively. TPH CL, the volume of distribution (Vd), and $t_{1/2}$ were decreased. These observations suggest that heartwood inhibits CYP1A enzymes and P-gp (P-glycoprotein) activity.\textsuperscript{4}

**Angelica species**

*Angelica rhizome*, (Umbelliferae), is promoted as a functional food supplement for women's health, a sedative, anodyne, and/or tonic agent in Asia. Three different *Angelica* species have been recorded to contain the most active principle, decursin\textsuperscript{44}. Decursin, has various pharmacological properties, including anticancer, anti-bacterial, platelet aggregation inhibitor and anti-inflammatory effects.\textsuperscript{45} A study has pointed out that decursin suppressed the activities of CYP1A2, CYP2D15, and CYP3A12 in canine liver microsomes.\textsuperscript{46} A recent in vitro investigation revealed that decursin derivatives had a potential therapeutic benefit in the treatment of asthma.\textsuperscript{47} A study investigated the impact of decursin on the PK of TPH, a typical substrate of CYP1A2 isoenzyme in rats. When TPH (10 mg/kg) was given, CL, elimination rate constant (Ke) of TPH were substantially reduced, whereas AUC, $C_{max}$, and $t_{1/2}$ were increased in decursin (25 mg/kg) pretreatment. Based on these results, pretreatment of decursin decreased the elimination of TPH. So, chronic use of decursin with TPH concomitantly could elevate the concentration of TPH in the blood. There are suggestions about the interaction of decursin with CYP1A2 substrates.\textsuperscript{48}

**Astragalus species**

*Astragaloside IV* (AGS-IV) is a triterpene glycoside derived from the radix of *Astragalali* which has different pharmacological properties such as antihypertensive cardio-tonic, antioxidant, anti-inflammatory, and antiviral actions. The effect of AGS-IV on the CYP1A2 isoenzyme was studied in vitro with phenacetin and in vivo with TPH. AGS-IV inhibited the activity of CYP1A2 isoenzyme and influenced the PK parameters of TPH in rats.\textsuperscript{48}

**Cassia auriculata and Cardiospermum halicacabum**

Herbal teas made from dried flowers of *C. auriculata* (Leguminosae) and aerial portions of *C. halicacabum* (Sapindaceae) are most widely consumed in Sri Lanka. *C. auriculata* is considered to be beneficial for individuals suffering from diabetes mellitus, constipation, and diseases of the urinary tract, while *C. halicacabum* is reputed to be beneficial for rheumatism, nervous diseases, digestive, and pulmonary disorders. In the past, a study was established to determine the impact of co-administration of teas prepared from *C. auriculata* or *C. halicacabum* with TPH, on the steady-state serum levels of the prescribed TPH, using rats as an experimental model. When TPH was given concurrently with herbal tea made from either of the above herbs, the results showed a significant increase in steady-state levels of TPH. *C. auriculata* and *C. halicacabum* enhanced steady-state levels of TPH by 32.5% and 48.2%, respectively, when compared with the levels in animals receiving...
TPH alone at the same time\textsuperscript{49}. Herbal preparations from the aforementioned herbs should be avoided by patients treated with TPH as these two herbs have the potential to influence the bioavailability of TPH.

**Scutellariae baicalensis**

Baicalin, a flavone glucoronide, is one of the major flavonoidal compounds of *Scutellariae* radix, the root of *Scutellariae baicalensis*. Baicalin has been used as a phytochemical marker for quality control in TCM. Also, baicalin has been reported to possess different pharmacological actions, including anti-allergic, anti-inflammatory and antioxidant properties\textsuperscript{50}. The binding of baicalin to human plasma proteins was between 86\% and 92\%\textsuperscript{51}. In a study that focused on plasma protein binding and the influence on CYP1A2, the effect of baicalin on the PK of TPH in rats was investigated. C\textsubscript{max} was remarkably increased by 43\% and Vd was decreased by 29\% for unbound TPH in rats treated with different dosage regimens of baicalin. Baicalin resulted in alterations in C\textsubscript{max}, t\textsubscript{1/2}, CL, and AUC of TPH by two mechanisms: plasma protein binding displacement and CYP1A2 activity suppression\textsuperscript{52}.

**Herbs with insignificant effect on tph metabolism**

**Nigella sativa**

*Nigella sativa* (Ranunculaceae) usually known as black seed, is an annual herb that grows in Mediterranean-coastal regions. Over a thousand years, the seeds have been recognized as a natural treatment to enhance health and treat ailments\textsuperscript{53}. For example, the oil of *Nigella sativa* is used as a traditional medicine for the treatment of arthritis, lung diseases, and hypercholesterolemia\textsuperscript{54\&55}. Some important constituents of the seeds include thymoquinone, nigellone, and isoquinoline alkaloid. Thymoquinone is reported to be an effective antimicrobial and anthelmintic agent. It may also play a role in women’s health, stimulating menstruation, and increasing milk flow\textsuperscript{56}. A study investigated the influence of black seed on the PK of TPH in beagle dogs. The black seed treatment group had no significant effect on TPH disposition as determined by C\textsubscript{max}, t\textsubscript{max}, AUC\textsubscript{0–t}, and CL\textsuperscript{53}.

**Cassia occidentalis**

*Cassia occidentalis*, (Caesalpiniaee), is an ayurvedic medicinal herb. It is also known by other names, e.g. coffee senna, fetid cassia, and negro coffee. It has been found to possess significant antibacterial, antifungal, analgesic, laxative, and diuretic features. The main phytochemicals present in *C. occidentalis* include achorson, aloë-edomin, emodin, and anthraquinones\textsuperscript{57}. When ethanolic extract of *C. occidentalis* was co-administered with TPH in rats, no differences in TPH bioavailability were identified when compared to methotrexate, methylprednisolone, and acetaminophen groups\textsuperscript{58}.

**Pomegranate and Licourice**

Pomegranate, *Punica granatum* has gained popularity as a natural antioxidant that may be taken as a fruit or juice\textsuperscript{59\&60}. However, it showed PK interactions with antiarrhythmics, calcium channel blockers, and statins\textsuperscript{61}. Pomegranate juice has been proven to inhibit CYP3A and to interfere with the intestinal absorption of certain drugs, most likely due to the modulation of transporters involved in the absorption process\textsuperscript{62\&63}. Licorice, *Glycyrrhiza glabra*, is a famous well-known traditional drink, particularly in the Middle East. However, licorice was observed to interact with some drugs like digoxin, thiazides, and spironolactone\textsuperscript{64}. Licorice was also found to impair cyclosporine bioavailability by interacting with P-gp and CYP3A4 enzyme\textsuperscript{65}. A preliminary report showed that one-week administration of aqueous licorice extract did not affect the PK of midazolam, a CYP3A4 substrate\textsuperscript{66}. However, both glycyrrhizin and glycyrrhetic acid have recently been proved to induce CYP3A4 in human\textsuperscript{67\&68}. A study was performed to determine the impact of pomegranate and licorice on TPH in rats. Findings showed that there was no interaction between pomegranate or licorice and TPH in rats. This was expressed by statistically non-significant differences between (C\textsubscript{max}, t\textsubscript{max} and AUC\textsubscript{0–24} hr) between groups of rats that received TPH alone and those which received TPH with pomegranate juice or licorice juice orally. If extended to humans, this might be important in terms of providing information about TPH administration and usage. So, consumption of pomegranate or licorice juice
before oral intake of TPH did not result in significant PK interaction.

**Ginkgo biloba**

The extract of Ginkgo biloba contains many compounds, including flavonoids such as ginkgetin and bilobetin, which account for 27% of the extract. Another phytochemical category is ginkgolides, such as A, B, and C bilobalide, which make up 22% of the standardized extract. In vitro and in vivo, ginkgo has been shown to have some small effects on CYP1A2. Ginkgo has been found to affect CYP2C9, CYP2D6 and CYP1E2 in vitro and in rat, but studies employing the specific probe substrates have revealed no clinically important effect. However, the impact of ginkgo on CYP3A4 is unclear (induction and inhibition reported), but any effect appears to be minor at best.

In an experimental study in rats pretreated with oral Ginkgo extract 100 mg/kg for 5 days, the serum level and AUC of a single 10 mg/kg oral dose of TPH given on day 6 were reduced by about 20% and 40% respectively, and a 70% increase of the CL was documented. Activation of CYP1A2 by ginkgo is thought to be the cause of this interaction. Increasing the activity of this isoenzyme allows TPH to be metabolized and eliminated more quickly. Only experimental evidence supports the interaction between ginkgo and TPH. However, a human study using caffeine as CYP1A2 probe substrate, found that ginkgo has not clinically relevant effect.

**St. John's wort**

Hypericum perforatum, sometimes known as St. John's wort (SJW), is an antidepressant herbal medication. The two main constituents are hyperforin and hypericin. P-gp regulated by hypericin, and hyperforin can induce CYP3A4, CYP2B6, and P-gp. SJW has been thoroughly explored because it has been linked to several clinical interactions with standard medications.

The findings of two cases of herb-drug interaction in healthy subjects' study between SJW and TPH were different. In the first case, no PK interaction was found after two weeks of co-administration of SJW with TPH, whereas a patient required an increase in TPH dosage while he was taking SJW for two months. In the first case of a study in 12 healthy subjects, it has been found that a standardized preparation of SJW 300 mg (hypericin 0.27%) three times daily for 15 days had no significant effect on the plasma level of a single 400 mg daily oral dose of TPH. In the second case of the same study, it has been reported that a woman who had previously been stable for several months taking TPH 300 mg twice daily, was found to need a marked increase in her TPH dosage to 800 mg twice daily to achieve a serum level of 9.2 mg/L. Two months previously, she had started to take 300 mg of a SJW supplement (hypericin 0.3%) each day and when she stopped taking SJW, her serum TPH levels were doubled within 14 days to 19.6 mg/L and her TPH dosage was consequently reduced in spite of she was a smoker and subjected to other treatment regimens.

The mechanism of interaction is uncertain, but it has been suggested that treatment with SJW for 15 days was unlikely to induce the isoenzymes sufficiently to cause changes in TPH levels. SJW is regarded to have a limited potential to stimulate CYP1A2, whereas the second case should explain the considerable interaction over a two-months period. Furthermore, most clinically significant interactions with SJW are mediated by CYP3A4. However, it would be prudent to be mindful of the possibility of an interaction until more information is available. Patients should be aware of possible adverse effects with concurrent use.

**Rhodiola rosea**

Rhodiola is a herb that is widely utilized all over the world. It is classified as an adaptogen, and it is used to cope with stress, improve mood, and alleviate depression. Rosavins are regarded to be the most active constituents in Rhodiola. They are a complex series of monoterpene alcohol and phenylpropanoid glycosides such as rosin and rosarin. Rhodiola also contains flavonoids, β-sitosterol, tannins, and rhodiolosides. An in vitro study found that Rhodiola root extract inhibited CYP3A4 isozyme, but the extent of the inhibition increased with high concentrations of rosarin content. Rhodiola did not affect TPH, hence it appears unlikely to affect the metabolism of other drugs that are CYP1A2 substrates. Only experimental
evidence supports the interaction of rhodiola and TPH. Rats in a study were given a standardized rhodiola extract twice daily for 3 days with a single dose of aminophylline (an ethylenediamine salt of TPH), given one hour after the last dose of rhodiola. The PKs of TPH were slightly influenced by the rhodiola extract (less than 15% decrease in AUC). Data obtained from this single study appears to be limited, and cannot be directly applied to humans. However, the PK of TPH is unlikely to be affected by rhodiola extract in a clinically significant manner.

Conclusion
Asthmatic patients are increasingly turning to complementary and alternative therapies. Because TPH has a limited therapeutic index and high inter-individual PK variability, therapeutic monitoring of TPH serum levels is critical to avoid any unwanted events. When medicine with a limited therapeutic index (e.g., theophylline, warfarin, cyclosporine, tacrolimus, etc.) is involved, the interactions might have dangerous or perhaps even devastating consequences. Despite a rise in the amount of data available on medicinal herb interactions, there is still a scarcity of information on the pharmacodynamics and PKs of herb-drug interactions, as well as their complicated role. Enzyme induction is a process in which certain herbal medicines and/or medications cause an increase in biotransformation and, as a result, a decrease in efficacy due to rapid metabolism, while enzyme inhibition, on the other hand, can result in higher serum levels of the un-metabolized substance, increasing the risk of toxicity. This makes it challenging to characterize and forecast interactions, as well as gain knowledge about the mechanisms.

Changes in TPH bioavailability were reported by induction mechanism when it is used concomitantly with the following herbs: Andrographis paniculata, Commiphora myrrha, Ephedra species, Evodia rutaecarpa, Lepidium sativum, Sophora flavescens, Salvia miltiorrhiza, and Trigonella foenum-graecum as shown in Table 1. TPH bioavailability was increased by inhibition mechanism on CYP1A2 when co-administered with Acacia catechu, Angelica species, Astragalus species, Cassia auriculata, Cardiospermum halicacabum and Scutellariae baicalensis as shown in Table 2 meanwhile, concomitant use of TPH with Cassia occidentalis, Glycyrrhiza glabra, Ginkgo biloba, Hypericum perforatum, Nigella sativa., Punica granatum and Rhodiola rosea as illustrated in Table 3 were reported to be statistically insignificant.

Table 1: Herbs with inductive effect on TPH metabolism:

| Herb                        | Synonym      | Mechanism of interaction | Effect                                      | Model   | Reference |
|-----------------------------|--------------|--------------------------|---------------------------------------------|---------|-----------|
| Andrographis paniculata     | Kalmegh      | Induced expression of CYP1A2 | TPH clearance significantly increased       | Rat     | 22        |
| Commiphora myrrha           | Myrrh        | Induced CYP1A2            | TPH blood level markedly decreased          | Rabbit  | 26        |
| Ephedra species             | Ma huang     | Potent inducer of CYP1A2  | Metabolism highly increased, TPH serum level decreased | Rat     | 27        |
| Evodia rutaecarpa            | Wu-Chu-Yu    | Potent inducer of CYP1A2  | TPH level significantly decreased           | Rat     | 10        |
| Lepidium sativum            | Garden cress | Induced CYP1A2            | TPH serum level decreased                   | Beagle dogs | 33        |
| Sophora flavescens          | Kushen       | Induced CYP1A2 and accelerated elimination | TPH concentration decreased | Rat     | 35        |
| Salvia miltiorrhiza         | Danshen      | Induced CYP1A2            | Alcoholic extract highly induced CYP1A2 protein expression | Mice    | 38        |
| Salvia miltiorrhiza         | Danshen      | Induced CYP1A2            | Time to maximum TPH level slightly decreased, no changes in PK parameters | Human   | 39        |
| Trigonella foenum-graecum   | Fenugreek    | Induced CYP1A2            | TPH serum level decreased                   | Beagle dogs | 33        |
**Table 2**: Herbs with inhibitory effect on TPH metabolism:

| Herb                        | Synonym       | Mechanism of interaction | Effect                                      | Model   | Reference |
|-----------------------------|---------------|---------------------------|---------------------------------------------|---------|-----------|
| *Acacia catechu*            | Black cutch   | Inhibited both CYP1A2 and P-gp | TPH serum level significantly increased     | Rabbit  | 4         |
| *Angelica species*          | Dong quai     | Inhibited CYP1A2          | TPH blood serum levels increased             | Rat     | 45        |
| *Astragalus species*        | Milkvetch     | Inhibited CYP1A2          | TPH blood serum levels increased             | Rat     | 48        |
| *Cassia auriculata*         | Avaram senna  | Inhibited CYP1A2          | Enhanced TPH steady-state levels             | Rat     | 49        |
| *Cardiospermum halicacabum* | Balloon vine  | Inhibited CYP1A2          | Enhanced TPH steady-state levels             | Rat     | 49        |
| *Scutellariae baicalensis*  | Baikal skullcap| Inhibited CYP1A2 Plasma protein binding displacement | TPH serum significantly increased           | Rat     | 52        |

**Table 3**: Herbs with insignificant effect on TPH metabolism:

| Herb                        | Synonym       | Mechanism of interaction | Effect                                      | Model   | Reference |
|-----------------------------|---------------|---------------------------|---------------------------------------------|---------|-----------|
| *Cassia occidentalis*       | Coffee senna  | Not found                 | Not significant                             | Rat     | 58        |
| *Glycyrrhiza glabra*        | Licorice      | No relevant interaction   | Not significant                             | Rat     | 69        |
| *Ginkgo biloba*             | Ginkgo        | Minor CYP1A2 induction    | TPH serum level decreased                   | Rat     | 74        |
| *Ginkgo biloba*             | Ginkgo        | Minor CYP1A2 induction    | No effect                                   | Human   | 75        |
| *Hypericum perforatum*     | St. John’swort| Uncertain                 | No significant outcomes, TPH serum level decreased in one case of clinical study | Human   | 78        |
| *Nigella sativa*            | Black seed    | No relevant interaction   | Not significant                             | Beagle  | 33        |
| *Punica granatum*           | Pomegranate   | No relevant interaction   | Not significant                             | Rat     | 69        |
| *Rhodiola rosea*            | Rose root     | Unlike to affect CYP1A2   | Not significant, TPH level slightly decreased| Rat     | 82        |
In vitro research, animal studies, and individual case reports provide the majority of the scientific evidence regarding TPH's interactions with medicinal herbs, but clinical studies are rare and meta-analyses are not reported in the literature. New interactions between TPH and medicinal herbs are likely to emerge as a result of the widespread use of herbal supplement therapy with TPH, which must be within the therapeutic range.

Because the results of the in vitro and in vivo experiments cannot be extrapolated to humans, there is no way to predict how TPH may interact with herbal supplements in humans. This approach can lead to additional studies of putative interactions between TPH and some bioactive components of medicinal herbs. When patients are treated with a TPH regimen in combination with other herbs, each case report must be accurately documented, carefully analyzed, and revised. Co-administration of herbal supplements should be closely monitored.

Acknowledgments

The authors wish to express deepest gratitude and thanks to all staff in the Faculty of Pharmacy at Azhar University-Gaza for their kind support.

REFERENCES

1. P. J. Barnes, "Theophylline", *Pharmaceuticals*, 3, 725-747 (2010).
2. A. Ohnishi, M. Kato, and J. Kojima, *et al.*, "Differential pharmacokinetics of theophylline in elderly patients", *Drugs & Aging*, 20(1), 71-84 (2003).
3. N. Rugelj, K. Trobec, and M. Pišlar *et al.*, "Evaluation of theophylline therapeutic drug monitoring service", *Zdrav Vestn*, 84, 191–202 (2015).
4. A. Al-Mohizea, M. Raish, and A. Ahad, *et al.*, "Pharmacokinetic interaction of *Acacia catechu* with CYP1A substrate theophylline in rabbits", *J Tradit Chin Med Sci*, 35(5), 588-593 (2015).
5. A. Jafari, S. Dadkhahfar, and S. Perseh, "Considerations for interactions of drugs used for the treatment of COVID-19 with anti-Cancer treatments", *Crit Rev Oncol Hematol*, 151, 102982 (2020).
6. J. Wójcikowski, P. J. Danek, A. Basińska-Ziobroń and *et al.*, "In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug–drug interactions", *Pharmacol Rep*, 72(3), 612–621 (2020).
7. P. D. Blanc, L. Trupin, and G. Earnest *et al.*, "Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis: data from a population-based survey", *Chest*, 120(5), 1461-1467 (2001).
8. S. Shi, and U. Klotz, "Drug interactions with herbal medicines", *Clin Pharmacokinet*, 51(2), 77–104 (2012).
9. C. Tarirai, A. M. Viljoen, and J. H. Hamman, "Herb–drug pharmacokinetic interactions reviewed", *Expert Opin Drug Metab Toxicol*, 6(12), 1515–1538 (2010).
10. W. C. Jan, L. C. Lin, and F. C. Chieh, *et al.*, "Herb-drug interaction of *Evodia rutaecarpa* extract on the pharmacokinetics of theophylline in rats", *J Ethnopharmacol*, 102(3), 440-445 (2005).
11. M. S. Hossain, Z. Urbi, and A. Sule, *et al.*, "*Andrographis paniculata* (Burm. f.) Wall. ex Nees: a review of ethnobotany, phytochemistry, and pharmacology", *Sci World J*, 14, 28 (2014).
12. D. C. Jain, M. M. Gupta, and S. Saxena, *et al.*, "LC analysis of hepatoprotective diterpenoids from *Andrographis paniculata*", *J Pharm Biomed Anal*, 22(4), 705-709 (2000).
13. Y. C. Shen, C. F. Chen, and W. F. Chiou, "Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involved in its anti-inflammatory effect", *Br J Pharmacol*, 135(2), 399-406 (2002).
14. R.A. Kumar, K. Sridevi, and N.V. Kumar, *et al.*, "Anticancer and immunostimulatory compounds from *Andrographis paniculata*", *J Ethnopharmacol*, 92(2-3), 291-295 (2004).
15. P. Thisoda, N. Rangkadiok, and N. Pholphana, *et al.*, "Inhibitory effect of *Andrographis paniculata* extract and its active diterpenoids on platelet aggregation", *Pharmacol Rep*, 72(3), 612–621 (2020).
aggregation", *Eur J Pharmacol*, 553(1-3), 39-45 (2006).

16. C. Calabrese, S. H. Berman, and J. G. Babish *et al.*, "A phase I trial of andrographolide in HIV positive patients and normal volunteers", *Phytother Res*, 14(5), 333-338 (2000).

17. P. K. Singha, S. Roy, and S. Dey, "Protective activity of andrographolide and arabinogalactan proteins from *Andrographis paniculata* Nees. against ethanol-induced toxicity in mice", *J Ethnopharmacol*, 111(1), 13-21 (2007).

18. A. Jaruchotikamol, K. Jarukamjorn, and W. Sirisangtrakul *et al.*, "Strong synergistic induction of CYP1A1 expression by andrographolide plus typical CYP1A inducers in mouse hepatocytes", *Toxicol Appl Pharmacol*, 224(2), 156-162 (2007).

19. D. Pekthong, N. Blanchard, and C. Abadie *et al.*, "Effects of *Andrographis paniculata* extract and Andrographolide on hepatic cytochrome P450 mRNA expression and monoxygenase activities after in vivo administration to rats and in vitro in rat and human hepatocyte cultures", *Chem Biol Interact*, 179(2-3), 247-255 (2009).

20. D. Pekthong, H. Martin, and C. Abadie *et al.*, "Differential inhibition of rat and human hepatic cytochrome P450 by *Andrographis paniculata* extract and andrographolide", *J Ethnopharmacol*, 115(3), 432-440 (2008).

21. Z. Bao, S. Guan, and C. Cheng *et al.*, "A novel anti-inflammatory role for andrographolide in asthma via inhibition of the nuclear factor-kappaB pathway", *Am J Respir Crit Care Med*, 179(8), 657-665 (2009).

22. C. F. Chien, Y. T. Wu, and W. C. Lee *et al.*, "Herb-drug interaction of *Andrographis paniculata* extract and andrographolide on the pharmacokinetics of theophylline in rats", *Chem Biol Interact*, 184(3), 458-465 (2010).

23. R. Capasso, A. A. Izzo, and L. Pinto *et al.*, "Phytotherapy and quality of herbal medicines", *Fitoterapia*, 71, S58-S65 (2000).

24. P. Dolaro, B. Corte, and C. Ghelardini *et al.*, "Local anaesthetic, antibacterial and antifungal properties of sesquiterpenes from myrrh", *Planta Med.*, 66(4), 356-358 (2000).

25. A. Massoud, S. El Sisi, and O. Salama *et al.*, "Preliminary study of therapeutic efficacy of a new fasciolicidal drug derived from *Commiphora molmol* (myrrh)", *Am J Trop Med Hyg*, 65(2), 96-99 (2001).

26. F. I. Al-Jenoobi, A. Ahad, and M. Raish *et al.*, "Investigating the Potential Effect of *Commiphora myrrha* on the Pharmacokinetics of Theophylline, a Narrow Therapeutic Index Drug", *Drug Res (Stuttgart)*, 65(6), 312-316 (2015).

27. J. Tang, X. Zhou, and H. Ji *et al.*, "Effects of *Ephedra* Water Decoction and Cough Tablets containing *Ephedra* and *Liquorice* on CYP1A2 and the Pharmacokinetics of Theophylline in Rats", *Phytother Res*, 26(3), 470-474 (2012).

28. S. Jia, and C. Hu, "Pharmacological Effects of Rutacearpine as a Cardiovascular Protective Agent", *Molecules*, 15(3), 1873-1881 (2010).

29. E. Basch, C. Ulbricht, and G. Kuo *et al.*, "Therapeutic applications of fenugreek", *Altern Med Rev*, 8(1), 20-27 (2003).

30. P. Sowmya, and P. Rajyalakshmi, "Hypocholesterolemic effect of germinated fenugreek seed in human subjects", *Plant Foods Hum Nutr.*, 53(4), 359–365 (1999).

31. E. Steels, A. Rao, and L. Vitetta, "Physiological aspects of male libido enhanced by standardized *Trigonella foenum-graecum* extract and mineral formulation", *Phytother Res.*, 25(9), 1294–1300 (2011).

32. A. H. Gilani, N. U. Rehman, and M. H. Mehmood, *et al.*, "Species differences in the antiarrheal and antispasmodic activities of *Lepidium sativum* and insight into underlying mechanisms", *Phytother Res.*, 27(7), 1086–1094 (2013).

33. F. I. Al-Jenoobi, K. M. Alkharfy, and A. M. Al-Mohizea, *et al.*, "Effects of fenugreek, garden cress, and black seed on theophylline pharmacokinetics in beagle dogs", *Pharm Biol.*, 53(2), 296–300 (2015).
34. X. He, J. Fang, and L. Huang et al., "Sophora flavescens Ait.: Traditional usage, phytochemistry and pharmacology of an important traditional Chinese medicine", *J Ethnopharmacol*, 172, 10-29 (2015).
35. Ueng YF, Tsai CC, and Lo WS et al., "Induction of Hepatic Cytochrome P450s by the Herbal Medicine Sophora flavescens Extract in Rats: Impact on the Elimination of Theophylline", *Drug Metab Pharmacokinet*, 25(6), 560-567 (2010).
36. T. O Cheng, "Danshen: a popular Chinese cardiac herbal drug", *J Am Coll Cardiol*, 47, 1499-1500 (2006).
37. X. Y. Ji, B. K. Tan, and Y. Z. Zhu, "Salvia miltiorrhiza and ischemic diseases", *Acta Pharm Sin*, 21(12), 1089–1094 (2000).
38. Y. H. Kuo, Y. L. Lin, and M. J. Don et al., "Induction of cytochrome P450-dependent monoxygenase by extracts of the medicinal herb Salvia miltiorrhiza", *J Pharm Pharmacol*, 58(4), 521–527 (2006).
39. F. Qiu, G. Wang, and Y. Zhao et al., "Effect of danshen extract on pharmacokinetics of theophylline in healthy volunteers", *Br J Clin Pharmacol*, 65(2), 270–274 (2008).
40. B. Hazra, R. Sarkar, and N. B. Ghate et al., "Study of the protective effects of Katha (Heartwood Extract of Acacia catechu) in liver damage induced by iron overload", *J Environ Pathol Toxicol Oncol*, 32(3), 229-240 (2013).
41. J. Monga, C. S. Chauhan, and M. Sharma, "Chemopreventive efficacy of (+)-catechin-rich aqueous extract of Acacia catechu Willd. Heartwood against 7,12-dimethylbenz[a]anthracene-induced hepatocarcinoma in Balb/c mice", *J Environ Pathol Toxicol Oncol*, 31(4), 313-323 (2012).
42. J. Monga, C. S. Chauhan, and M. Sharma, "Human breast adenocarcinoma cytotoxicity and modulation of 7, 12-dimethylbenz [a] anthrancene-induced mammary carcinoma in Balb/c mice by Acacia catechu (L.f.) Wild heartwood", *Integr Cancer Ther*, 12(4), 347-362 (2013).
43. B. S. Negi, and B. P. Dave, "In vitro antimicrobial activity of Acacia catechu and its phytochemical analysis", *Indian J Microbiol*, 50(4), 369-374 (2010).
44. H. H. Kim, K. S. Ahn, and Han H et al., "Decursin and PDBu: two PKC activators distinctively acting in the megakaryocytic differentiation of K562 human erythroleukemia cells", *Leuk Res*, 29(12), 1407-1413 (2005).
45. J. W. Chae, I. H. Baek, and K. I. Kwon, "Effect of decursin on the pharmacokinetics of theophylline and its metabolites", *J Ethnopharmacol*, 144(2), 248-254 (2012).
46. A. M. El-Aty, S. S. Shah, and B. M. Kim et al., "In vitro inhibitory potential of decursin and decursinol angelate on the catalytic activity of cytochrome P-450 1A1/2, 2D15, and 3A12 isoforms in canine hepatic microsomes", *Arch Pharm Res*, 31(11), 1425-1435 (2008).
47. E. J. Yang, G. Y. Song, and J. S. Lee et al., "A novel (S)-(+) decursin derivative, (S)-(++)-3-(3,4-dihydroxy-phenyl)-acrylic acid 2,2-dimethyl-8-oxo-3,4-dihydro-2H,8H-pyrano[3,2-g]chromen-3-yl-ester, inhibits ovalbumin-induced lung inflammation in a mouse model of asthma", *Biol Pharm Bull*, 32(3), 444-449 (2009).
48. Y. H. Zhang, Y. J. Zhang, and Y. L. Guo et al., "Astragaloside IV inhibited the activity of CYP1A2 in liver microsomes and influenced theophylline pharmacokinetics in rats", *J Pharm Pharmacol*, 65(1), 149-155 (2013).
49. I. Thabrew, J. Munasinghe, and S. Chakrewarthi et al., "Effects of Cassia auriculata and Cardospermum halicacabum teas on the steady state blood levels of theophylline in rats", *Drug Metab Pharmacokinet, Drug Metabol Drug Interact*, 20(4), 263-272 (2004).
50. M. Y. Lai, S. L. Hsiu, and S. Y. Tsai et al., "Comparison of metabolic pharmacokinetics of baicalin and baicalein in rats", *J Pharm Pharmacol*, 55(2), 205–209 (2003).
51. Y. Tang, H. Zhu, and Y. Zhang et al., "Determination of human plasma protein binding of baicalin by ultrafiltration and
high-performance liquid chromatography", Biomed Chromatogr, 20(10), 1116-1119 (2006).
52. N. Gao, Y. Fang, and B. Qi "Pharmacokinetic changes of unbound theophylline are due to plasma protein binding displacement and CYP1A2 activity inhibition by baicalin in rats", J Ethnopharmacol, 150(2), 477-484 (2013).
53. H. Gali-Muhtasib, A. Roessner, and R. Schneider-Stock, "Thymoquinone: A promising anti-cancer drug from natural sources", Int J Biochem Cell Biol, 38(8), 1249–1253 (2006).
54. K. M. Alkhafri, F. I. Al-Jenoobi, and M. A. Alam, "Lepidium sativum but not Nigella sativa affects carbamazepine disposition in an animal model", Drug Metab Lett, 7(1), 47–51 (2013b).
55. M. Khader, N. Bresgen, P. M. Eckl, "In vitro toxicological properties of thymoquinone", Food Chem Toxicol, 47(1), 129–133 (2009).
56. I. A. Ajayi, R. A. Oderinde, and D. O. Kajogbola "Oil content and fatty acid composition of some underutilized legumes from Nigeria", Food Chem, 99(1), 115–120 (2006).
57. J. P. Yadav, V. Arya, and S. S. Yadav Cassia occidentalis L.: "A review on its ethnobotany, phytochemical and pharmacological profile", Fitoterapia, 81(4), 223-230 (2010).
58. A. Husain, M. Riyazuddin, and R. Katekar "Herb–drug interaction studies of ethanolic extract of Cassia occidentalis L. coadministered with acetaminophen, theophylline, omeprazole, methotrexate and methylprednisolone", Phytomedicine Plus, 1(1),100008 (2021).
59. K. E. Komperda, "Potential interaction between pomegranate juice and warfarin", Pharmacotherapy, 29(8), 1002-1006 (2009).
60. R. Awad, E. Mallah, and B. Al Khawaja "Pomegranate and licorice juices modulate metformin pharmacokinetics in rats", Neuro Endocrinol Lett, 37(3), 202-206 (2016).
61. W. A. AbuDayyih, E. M. Mallah, and I. H. AL-Ani "Licorice beverage effect on the pharmacokinetic parameters of atorvastatin, simvastatin, and lovastatin by liquid chromatography-mass spectroscopy/ mass spectroscopy", Asian J Pharm Clin Res, 9(2), 174-179 (2016).
62. M. Hidaka, M. Okumura, and K. Fujita "Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats", Drug Metab Dispos, 33(5), 644-648 (2005).
63. M. Hamad, W. A. AbuDayyih, and R. Raad "The Effect of Some Fruit Juices on Glimepiride Pharmacokinetic in Rat Plasma by Using High Performance Liquid Chromatography Mass Spectrometry", Biomed Pharmacol, 10(4), 1665-1675 (2017).
64. T. Al-Shaikhli, W. Abu Dayyih, and E. Mallah "Determination of Atorvastatin Pharmacokinetic Parameters by LC/MS-MS with Traditional Liquorice Beverage", Adv anal chem, 5(1), 17-24 (2015).
65. Y. T. Chua, X. L. Ang, and X. M. Zhong "Interaction between warfarin and Chinese herbal medicines", SMJ(1), 56, 11-18 (2015).
66. J. H. Shon, J. Y. Park, and M. S. Kim "Effect of licorice (radix glycyrrhizae) on the pharmacokinetics and pharmacodynamics of midazolam in healthy subjects", Clin Pharmacol Ther, 69(2), P78 (2001).
67. H. Y. Li, W. Xu, and J. Su "In vitro and in vivo inhibitory effects of glycyrrhetinic acid on cytochrome P450 3A activity", Pharmacology, 86(5-6), 287–292 (2010).
68. J. H. Tu, D. L. Hu, and L. L. Dai "Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes", Xenobiotica, 40(6), 393–399 (2010).
69. A. Alanbaki, I. Aliani, and E. Mallah "The effect of pomegranate and Licorice on Pharmacokinetics of Theophylline in Rats", Fasad J Pharm Sci, 44(1), 9-16 (2019).
70. H. J. Gertz, and M. Kiefer, "Review about Ginkgo biloba special extract (EGb 761 (Ginkgo))", Curr Pharm Des, 10(4), 261-264 (2004).
71. C. Gaudineau, R. Beckerman, and S. Welbourn "Inhibition of human P450
enzymes by multiple constituents of the Ginkgo biloba extract", *Biochem Biophys Res Commun*, 318(4), 1072–1078 (2004).
72. T. Sugiyama, Y. Kubota, and K. Shinozuka "Induction and recovery of hepatic drug metabolizing enzymes in rats treated with Ginkgo biloba extract", *Food Chem Toxicol*, 42(6), 953–957 (2004).
73. B. H. Hellum, Z. Hu, and O. G. Nilsen, "The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes", *Basic Clin Pharmacol Toxicol*, 100(1), 23–30 (2007).
74. J. Tang, J. Sun, and Y. Zhang "Herb-drug interactions: Effect of Ginkgo biloba extract on the pharmacokinetics of theophylline in rats", *Food Chem Toxicol*, 45(12), 2441–2445 (2007).
75. B. J. Gurley, S. F. Gardner, and M. A. Hubbard "Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans", *Clin Pharmacol Ther*, 72(3), 276–87 (2002).
76. Y. M. Di, C. G. Li, and C. C. Xue "Clinical drugs that interact with St. John’s wort and implication in drug development", *Curr Pharm Des*, 14(17), 1723-1742 (2008).
77. J. Wentworth, M. Agostini, and J. Love "St. John's wort, a herbal antidepressant, activates the steroid X receptor", *J Endocrinol*, 166, R11-16 (2000).
78. T. Morimoto, T. Kote, and K. Tsutsumi "Effect of St. John’s wort on the pharmacokinetics of theophylline in healthy volunteers", *J Clin Pharmacol*, 44(1), 95–101 (2004).
79. A. Nebel, B. J. Schneider, and R. K. Baker "Potential metabolic interaction between St. John’s wort and theophylline", *Ann Pharmacother*, 33(4), 502 (1999).
80. A. R. Bilia, S. Gallori, and F. F. Vincieri, "St. John's wort and depression: efficacy, safety and tolerability—an update", *Life Sci*, 70(26), 3077-3096, (2002).
81. I. M. Scott, R. I. Leduc, and A. J. Burt "The inhibition of human cytochrome P450 by ethanol extracts of North American botanicals", *Pharm Biol*, 44(5), 315–327 (2006).
82. A. Panossian, A. Hovhannisyan, and H. Abrahamyan "Pharmacokinetic and pharmacodynamic study of interaction of Rhodiola rosea SHR-5 extract with warfarin and theophylline in rats", *Phytother Res*, 23(3), 351-357 (2009).
دراسة استعراضية لتفاعلات الدوائية للثيوφيلين مع الأعشاب الطبية

مصطفى محمد أبو شمالة* - عدنان محمد حمدان
قسم الصيدلانيات والصيدلية الصناعية، كلية الصيدلة، جامعة الأزهر، غزة، فلسطين. صندوق بريد 1477.

الثيوφيلين (TPH) هو موسوعة قصبي مؤشر علاجي محدود ذو حركة دوائية متقلبة بين الأفراد. تعد التفاعلات المحتملة بين الأدوية والأعشاب مصدر فلق كبير للسلامة، خاصة بالنسبة للأدوية ذات المؤثرات العلاجية القوية، مثل TPH، والتي يمكن أن تؤدي إلى أثار ضارة خطيرة تهدد الحياة. في هذه الورقة، تم تحليق التفاعلات بين TPH والأعشاب الطبية المسجلة في الأدبيات وتم التحقيق والبحث للمراعي التي تم تحليلها. تم الإبلاغ عن انخفاض في التوافر الحيوي لـ TPH أثناء إعطائها مع بعض الأعشاب أو المستخلصات العشبية (Andrographis paniculata، Cardiospermum halicacabum، Scutellariae baicalensis، Hypericum perforatum، Ginkgo biloba، Cassialycyralis) مع TPH Request (1). كما تم زيادة التوافر الحيوي لـ (graecum CYP1A2) بواسطة آلية التثبيت على TPH بالاشتراك مع الأعشاب (أكاسيا كاتشو، أنجيليكا، أنواع استراغالوس، وكاسيا أوريكولاتا، و (Scutellariae baicalensis و Cardiospermum halicacabum و Nigella sativa و Hypericum perforatum و Ginkgo biloba و Cassialycyralis) مع TPH (2). تم الإبلاغ عنها بأنها أحياناً غير ذات أهمية. في هذه المراجعة، ركزنا على التفاعلات بين TPH والأعشاب الطبية التي لم يتم تغطيتها في الدراسات السابقة. لتقليل المخاطر الصحية للمرضى والتي من المتوقع أن تخدم المتخصصين في المجال الصحي.